The American College of Cardiology (ACC) develops a wide range of policy documents to
provide members with guidance on clinical topics. Although Clinical Practice Guidelines …

2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk
Reduction in Patients With Type 2 Diabetes: A Report of the American College of …

The prevalence of diabetes continues to increase, with 60 million thought to have diabetes
in Europe in 2017 and predictions of more than 600 million individuals with diabetes …

Abstract The 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes &
Cardiovascular Disease (D&CVD) EASD Study Group was held in Munich on 25–26 …

The American College of Cardiology (ACC) develops a number of clinical policy documents
to provide members with guidance on clinical topics. Although clinical practice guidelines …

Background Evidence‐based therapies are generally underused for cardiovascular risk
reduction; however, less is known about contemporary patients with type 2 diabetes mellitus …

Responding to concerns about the potential for increased risk of adverse cardiovascular
outcomes, specifically myocardial infarction, associated with certain glucose-lowering …

Importance Evidence-based therapies to reduce atherosclerotic cardiovascular disease risk
in adults with type 2 diabetes are underused in clinical practice. Objective To assess the …

• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

In December 2008, the US Food and Drug Administration issued guidance to the
pharmaceutical industry setting new expectations for the development of antidiabetes drugs …